Sanofi-Aventis buys rights to insulin delivery tech

French drugmaker Sanofi-Aventis has bought the rights to a diabetes drug-delivery technology from Ascendis, an American and Danish pharmaceutical company. Sanofi says in a news release that the technology showed "promising results" with insulin in early tests.

Ascendis' technology, which it calls TransCon Linker, allows for precise, time-controlled, long-acting delivery of medication. It does this by creating transient bonds between larger molecules such as proteins and peptides, including insulin, and a carrier. The bonds allow for tailor-made release, according to the company, with no initial bursts.

Under the agreement, Sanofi will get the license to develop, manufacture and commercialize the technology in combination with active molecules for diabetes. Ascendis will receive an undisclosed upfront payment along with milestones.

- Bloomberg has the story
- and so does Dow Jones
- read the Sanofi press release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.